Clinical Trial Search

Primary: Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 — -1.1; -23.5; -23.2; -25.3 Percent change — p=<0.001

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 18; 13; 17; 1 Participants

Primary: Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale…

Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects

Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…

Primary: Percentage of Participants With Systolic BP Control — 76; 25 percentage of participants

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Fugl-Meyer Assessment Upper Limb Portion — 10.8; 6.4; 4.7 units on a scale — p=0.010

Primary: Visual Acuity — 0.32; 0.44 logMAR units

Primary: Evaluation of Patients With Adverse Events — 10 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 3; 3 Participants

Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants

Primary: Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale — 107; 10 Participants — p=<0.0001

Primary: Immediate Post-polypectomy Pain — 46.5; 13.6 units on a scale

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Concentration Curve From 0 to 6 Hours (AUC0-6 Hours) Over 12 Weeks — 258.6; 242.2…